AstraZeneca: Imfinzi a success in lung cancer

(CercleFinance.com) - AstraZeneca announced on Thursday that one of its flagship immunotherapies, Imfinzi, has succeeded in improving the survival of patients with a form of lung cancer whose tumour is operable.


The phase III trial found that treatment with Imfinzi before and after surgery "significantly" increased event-free survival (i.e. without recurrence or progression of the disease) in patients with non-small cell cancer.

Patients with non-small cell cancer face unacceptably high rates of disease recurrence, despite treatment with chemotherapy and surgery, AstraZeneca said.


Copyright (c) 2023 CercleFinance.com. All rights reserved.